Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pharmaron","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Pharmaron","sponsor":"Immuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmaron

    Menu

    Pharmaron

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pharmaron

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron

              Details:

              The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.

              Lead Product(s): Bovine Colostrum

              Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan

              Highest Development Status: IND Enabling Product Type: Large molecule

              Recipient: Immuron

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pharmaron

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A

              Details:

              OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).

              Lead Product(s): OLX703A

              Therapeutic Area: Infections and Infectious Diseases Product Name: OLX703A

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: OliX Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY